Business Context and Reporting Period
This Form 8-K is filed by eXegenics Inc. (not OPKO Health, Inc.) for the reporting period of September 1, 2004. The company is a Delaware corporation focused on drug discovery technology, specifically its QCT (Quantum Chemical Theory) platform.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to a potential future revenue stream from a new agreement.
Material Changes and Events
- Material Definitive Agreement: On September 8, 2004, eXegenics entered into an Intellectual Property Assignment Agreement with NLC Pharma, Inc. (Israel). The company will license its QCT drug discovery technology to NLC Pharma and is eligible to receive up to $20 million in royalties, license fees, or proceeds from third-party sales generated by NLC Pharma.
- NASDAQ Delisting Notice: On September 1, 2004, the company received notice from NASDAQ regarding non-compliance with independent director and audit committee requirements due to the retirement of John Huntz. Additionally, the company remains non-compliant with the minimum $1.00 closing bid price requirement (notified July 26, 2004), which led to a delisting effective August 4, 2004.
- Corporate Governance Change: On September 8, 2004, the board appointed David Lee Spencer as the third independent director of the audit committee to address governance deficiencies.
Outlook, Risks, and Contingencies
Listing Status Risk: The company faces an imminent risk of continued delisting from the NASDAQ SmallCap Market. A listing qualifications hearing is scheduled for September 9, 2004, to address both the bid price deficiency and the independent director/audit committee compliance issues.
Management Commentary: The company is actively seeking to resolve listing deficiencies by appointing a new independent director and appealing the delisting determination.
Investor Verification Checklist
- Verify the outcome of the September 9, 2004, NASDAQ listing qualifications hearing regarding the bid price and governance compliance.
- Confirm the specific terms and milestones required to realize the potential $20 million from the NLC Pharma agreement.
- Check the current trading status of the stock following the August 4, 2004, delisting notice.
- Review the company's capital position, as this filing does not disclose current cash reserves or debt levels.